Objective TIGIT/CD155 has attracted widespread attention as a new immune checkpoint and
a potential target for cancer immunotherapy. In our study, we evaluated the role of …

CD155/T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a novel type of immune
checkpoint. CD155 is an adhesion molecule that is upregulated during tumor progression …

Immunosuppression is common in head and neck squamous cell carcinoma (HNSCC). In
previous studies, the TIGIT/CD155 pathway was identified as an immune-checkpoint …

Background Novel therapies are needed to treat recurrent and advanced cervical cancer
(CC), as their prognosis remains very poor. Although therapies targeting the programmed …

TIGIT, an immune checkpoint molecule widely expressed on NK cells, activated T cells and
Tregs, has been involved in delivering inhibitory signals through the interaction with PVR …

T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on
lymphocytes that was recently propelled under the spotlight as a major emerging target in …

Ovarian cancer (OC) is the fifth‐leading cause of cancer‐related death in women with a
pathogenesis involving activation of regulatory T cells (Tregs). The T‐cell immunoglobulin …

Immune evasion through up-regulating checkpoint inhibitory receptors on T cells plays an
essential role in tumor initiation and progression. Therefore, immunotherapy, including …

Recently, T-cell immunoreceptor with Ig and ITIM domains (TIGIT) was reported as a
candidate for novel immune checkpoints. However, the impact of TIGIT on melanoma …

Objective Targeting immune checkpoints, such as PD-1, represents a promising approach
for cancer immunotherapy, achieving long-term disease remission rates in numerous types …